The global pharmaceutical industry is a multi-trillion-dollar industry and the possibility of a policy that could lower drug prices and potentially their profit, may have them shaking in their lab coats.
Former President Donald Trump is reportedly exploring a controversial move to lower U.S. drug prices by tying them to significantly cheaper international rates—a strategy that could dramatically reshape pharmaceutical policy and spark fierce debate among lawmakers, healthcare providers, and the drug industry. As he is settling into his return to the political stage, this proposal signals a renewed focus on domestic affordability in an era of skyrocketing medication costs. Could this be a game-changing reform or a regulatory storm in the making? Read the full article on Reuters